Clinical trial
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and…
NCT00193284 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193284 |
|---|---|
| Title | Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer |
| Official title | A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | AstraZeneca Industry Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Docetaxel, Carboplatin, Fluorouracil |
| Enrollment | 50 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 22, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: